RxDoctor Payments Data

Rajnikant Patel, MD

Family Medicine · Ocala, FLNPI 1407816242

Payments from drug & device makers

$3,813in general payments, 2019–2025

Across 46 payments — averaging $82.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$968
  • Ironwood Pharmaceuticals, Inc$391
  • AstraZeneca$331
  • Novartis$287
  • Amarin Pharma, Inc.$283
  • Stryker$253
  • plus $1K from 12 others

What the payments were for

  • Food & beverage$3,807100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,813 in reported general payments places this provider in the 80th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$224,377
Medicare patients
270
Services billed
9,787

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban72$105,193
MounjaroTirzepatide61$61,046
OzempicSemaglutide52$60,942
JanuviaSitagliptin Phosphate43$44,620
JardianceEmpagliflozin31$36,620
XareltoRivaroxaban17$19,737
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$18,035
EntrestoSacubitril/Valsartan12$17,759
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog14$16,047
JanumetSitagliptin Phos/Metformin Hcl13$15,073
Tresiba Flextouch U-100Insulin Degludec15$10,854
Albuterol Sulfate HfaAlbuterol Sulfate112$4,782
Atorvastatin Calcium414$3,519
Gabapentin161$3,471
Levemir FlexpenInsulin Detemir13$3,098

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$52$61,04661 claims
Novo NordiskOzempic$230$60,94252 claims
Boehringer IngelheimJardiance$92$36,62031 claims
Johnson & JohnsonXarelto$968$19,73717 claims
GSKTrelegy Ellipta$27$18,03512 claims
NovartisEntresto$287$17,75912 claims
AbbVieSynthroid$146$79818 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Ocala

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →